Stock comparison
Becton, Dickinson and
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BDX
Becton, Dickinson and
Market cap
$53.46B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BDX | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 79B | HALO |
| Benjamin Graham | 57C | 83A | HALO |
| Philip Fisher | 36D | 65B | HALO |
| Peter Lynch | 15F | 53D | HALO |
| Joel Greenblatt | 40D | 40D | Tie |
| Charlie Munger | 39D | 80C | HALO |
| Terry Smith | 39D | 84A | HALO |
Side-by-side metrics
| Metric | BDX | HALO |
|---|---|---|
| Market cap | $53.46B | $8.1B |
| P/E (TTM) | 35.3x | 24.0x |
| EV/EBIT | 26.5x | 10.2x |
| ROIC (TTM) | 4.1% | 23.65% |
| Gross margin | 46.48% | 81.24% |
| Net margin | 5.33% | 23.13% |
| Revenue CAGR 5y | 3.37% | 33.23% |
| EPS CAGR 5y | -4.15% | -1.98% |
| Debt / Equity | 0.7x | 1.0x |
| Dividend yield | 2.45% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BDX leads on
- Dividend yield2.45%vs 0.0%+100%
- Market cap$53.46Bvs $8.1B+85%
- Debt / Equity0.7xvs 1.0x+25%
HALO leads on
- Revenue CAGR 5y33.23%vs 3.37%+90%
- ROIC (TTM)23.65%vs 4.1%+83%
- Net margin23.13%vs 5.33%+77%
- EV/EBIT10.2xvs 26.5x+62%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.